Aim:

To assess the efficacy and limitation of free/total prostate-specific antigen ratio (f/tPSA) at a single institution in Japan, focusing on the avoidance of pointless prostate biopsies.

Methods:

In total, 631 men between 44 and 93 years old (mean 69.8 years) with elevated PSA underwent power-Doppler ultrasoundgraphy-guided transrectal 10-core prostate biopsies at Niigata Cancer Center Hospital, and their histological features were investigated with total PSA (tPSA) and f/tPSA.

Results:

PCa was detected in 126 of 134 patients (94.3%) with tPSA of 26 ng/mL or higher. The detection rate was 59.4% for tPSA of 21–25 ng/mL, followed by 39.2% for 16–20 ng/mL, 30.0% for 11–15 ng/mL, 20.0% for 4.1–10 ng/mL and 7.6% for 4.0 ng/mL. f/tPSA of the PCa group was significantly lower than that of non-malignamt disorders in any tPSA ranges (mean 0.122 vs. 0.160, P < 0.001). Receiver-operating characteristics analyses showed that f/tPSA (AUC: 0.664) performed more valuably than tPSA (AUC: 0.559) in patients with tPSA between 3.0–10 ng/mL (P < 0.01). Although f/tPSA of 0.250 for the cut-off value might miss 1.8% PCa patients, it potentially spares 9.2% of unnecessary biopsies.

Conclusion:

f/tPSA is more valuable compared with tPSA alone for the prediction of the occurrence of PCa. We recommend 0.250 as the cut-off value for f/tPSA in PCa screening for Asian men having so-called grey-zone tPSA.

References

1. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994; 152: 2037–42. | PubMed | ChemPort |
2. Hara N, Koike H, Ogino S, Okuizumi M, Kawaguchi M. Application of serum PSA to identify acute bacterial prostatitis in patients with fever of unknown origin or symptoms of acute pyelonephritis. Prostate 2004; 60: 282–8. | Article | PubMed |
3. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110–4. | PubMed | ISI | ChemPort |
4. Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, Benson MC. PSA density (PSAD) Role in patient evaluation and management. Urol Clin North Am 1993; 20: 653–63. | PubMed | ChemPort |
5. Hara N, Kasahara T, Kawasaki T, Bilim V, Obara K, Takahashi K, et al. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. Clin Cancer Res 2002; 8: 1794–9. | PubMed | ISI | ChemPort |
6. Partin AW, Catalona WJ, Southwick PC, Subong ENP, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 1996; 48: 55–61. | Article | PubMed | ChemPort |
7. Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer Part II. Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology 1995; 46: 779–84. | Article | PubMed | ChemPort |
8. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214–20. | Article | PubMed | ChemPort |
9. Recker F, Kwiatkowski MK, Pettersson K, Piironen T, Lummen G, Huber A, et al. Enhanced expression of prostate-specific antigen in the transition zone of the prostate A characterization following prostatectomy for benign hyperplasia. Eur Urol 1998; 33: 549–55. | Article | PubMed | ISI | ChemPort |
10. Taneja SS, Hsu EI, Cheli CD, Walden P, Bartsch G, Horninger W, et al. Complexed PSA (cPSA) as a surgical staging tool: results based upon a multicenter prospective evaluation of cPSAin cancer diagnosis. Urology 2002; 60: 10–7. | Article | PubMed |
11. Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 2005; 62: 140–7. | Article | PubMed |
12. Al-Ghazo MA, Ghalayini IF, Matalka II. Ultrasound-guided transrectal extended prostate biopsy: a prospective study. Asian JAndrol 2005; 7: 165–9. | Article |
13. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter N Engl J Med 2004; 350: 2239–46. Erratum in: N Engl J Med 2004; 351:1470. | Article | PubMed | ISI | ChemPort |
14. Fukagai T, Shimada M, Yoshida H, Namiki T, Carlile RG. Clinical-pathological comparison of clinical prostate cancer between Japanese Americans in Hawaii and Japanese living in Japan. Int J Androl 2000; 23: 43–4. | Article | PubMed |
15. Partin AW, LA Mangold, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 843–8. | Article | PubMed | ISI | ChemPort |
16. Gao HW, Li YL, Wu S, Wang YS, Zhang HF, Pan YZ, et al. Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen. Asian J Androl 2005; 7: 159–63. | Article | PubMed | ISI |
17. Horninger W, Volgger H, Rogatsch H, Gschwendtner A, Bartsch G. Consideration of low PSA cut-off levels to optimize the detection of curable prostate cancer. Eur Urol 2001: 39: 43–6. | Article | PubMed |
18. The Research Group for Population-based Cancer Registration in Japan: Cancer incidence in Japan. In: Tajima K, Kuroishi T, Oshima, A, Cancer Mortality and Morbidity Statistics: Japan and the World-2004. Tokyo: Japan Scientific Societies Press, 2004: 95–130.
19. Nakashima J, Kikuchi E, Ishibashi M, Oya M, Ohigashi T, Marumo K, et al. Value of PSA-related parameters in detecting prostate cancer. Jpn J Urol Surg 2001; 14: 445–6.
20. Kuriyama M. The evaluation of PSA molecular forms, molecular ratio, and PSAD in the cases showing slightly elevated serum PSA values for screening prostate cancer. Jpn J Urol Surg 1998; 11: 925–30.
21. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination Enhancement of specificity with free PSA measurements. JAMA 1997; 277: 1452–5. | Article | PubMed | ISI | ChemPort |
22. Egawa S, Suyama K, Takashima R, Mizoguchi H, Kuwao S, Baba S. Prospective evaluation of prostate cancer detection by prostate-specific antigen-related parameters. Int J Urol 1999; 6: 493–501. | Article | PubMed | ISI | ChemPort |
23. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1 000 consecutive patients. J Urol 2002; 167: 528–34. | Article | PubMed | ISI |
24. Tombal B, Querton M, de Nayer P, Sauvage P, Cosyns JP, Feyaerts A, et al. Free/total PSA ratio does not improve prediction of pathologic stage and biochemical recurrence after radical prostatectomy. Urology 2002; 59: 256–60. | Article | PubMed |

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.